Everand Logo

Welcome to Everand!

  • STAT

    STAT+: Pharmalittle: We’re watching more positive data for Ozempic, a Lilly factory expansion, and more

    by Adam Feuerstein May 24, 2024 1 minute
    Source: Alex Hogan/STAT

    It’s an honor to fill in for Ed Silverman this morning. There is only one Pharmalot, but when he’s out, his fellow STAT coffee and tea drinkers

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An ‘Unaffordable’ Novartis Drug, A Proposed Patent Rule, And More
    In today's Pharmalittle roundup, we're reading about an "unaffordable" Novartis drug, a new patent office rule, and more.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An FDA Meeting On MDMA, A New Obesity Pill, And More
    Structure Therapeutics disclosed that its oral obesity drug helped reduce weight by 6.2% on average in a mid-stage study, exceeding Wall Street expectations.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Merck Deal, Weight Loss Drugs, And Lots More
    Merck has struck a $1.3 billion deal to buy Eyebiotech, a move that would push the big drugmaker into the large and growing market for eye care.

    Related Books & Audiobooks